FDA warns that antidepressants may increase suicidality in adultsBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7508.70-b (Published 07 July 2005) Cite this as: BMJ 2005;331:70
- Jeanne Lenzer
- New York
The US Food and Drug Administration last week reiterated its warning that adults treated with antidepressants must be closely observed by their doctors in case they experience worsening of depression and “increased suicidal thinking or behavior.”
Agency officials simultaneously posted new information that a “higher than expected rate of suicide attempts was observed” among patients taking the antidepressant duloxetine (manufactured by Eli Lilly and marketed in the United States as Cymbalta).
Eli Lilly has objected to the FDA's warning about duloxetine. According to a report in the Wall Street Journal (1 July; …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial